CANbridge Pharmaceuticals Completes Enrollment in Phase II GBM Trial for CAN008
Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a...
Chongqing Genrix’s Xeligekimab for Psoriasis Accepted for Market Approval Review
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing...
Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022....
National ADR Monitoring Report Highlights Oncology Drugs and Elderly Patient Safety
The National Center for ADR Monitoring has published its “National Adverse Drug Reaction Monitoring Annual...
China’s New Internet Advertising Regulations Impact Pharmaceutical Sector
The State Administration for Market Regulation has released the latest version of the “Measures for...
Fosun Pharma Reports 12.66% YOY Revenue Growth and Increased R&D Investment in 2022 Financial Report
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...
CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has obtained an Emergency...
Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China
US-based medical device leader, Boston Scientific Corporation (NYSE: BSX), has announced the market launch of...
CDE Launches Technical Guidelines for Pediatric Anti-tumor Drug Development
The Center for Drug Evaluation (CDE) has released a set of Technical Guidelines focused on...
Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion and R&D
China-based Huaren Pharmaceutical Co., Ltd (SHE: 300110) is set to raise capital through the private...
CDE Issues New Guidance on Pre-Phase III Clinical Trial Meetings for Innovative Drugs
The Center for Drug Evaluation (CDE) has released the “Innovative Chemical Drug Pre-Phase III Clinical...
Zhaoke Ophthalmology Signs Distribution Agreement with Kwangdong for NVK002 in South Korea
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Gain Clinical Trial Approvals
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...
YHLO Biotech Partners with NCRCID to Develop Advanced Tuberculosis Diagnostics
China-based Shenzhen YHLO Biotech Co., Ltd has entered into a strategic partnership with the National...
Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation
China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront...
Akeso Biopharma and LaNova Medicines Collaborate on Clinical Studies for Cancer Therapies
China-based Akeso Biopharma (HKG: 9926) has announced a strategic partnership with fellow Chinese firm LaNova...
Lee’s Pharmaceutical Subsidiary Secures Distribution Deal for NVK002 in South Korea
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622),...
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Secure Clinical Trial Approvals for Solid Tumors
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...
Shenzhen YHLO Biotech Partners with NCRCID for Advanced Tuberculosis Diagnostics
China-based Shenzhen YHLO Biotech Co., Ltd has announced a strategic partnership with the National Clinical...
Everest Medicines Receives $280 Million from Gilead Sciences for Partnership Cancellation
China-based Everest Medicines (HKG: 1952) has announced that it has received a full upfront payment...